Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
letter
. 2020 May 8;98(1):236–237. doi: 10.1016/j.kint.2020.04.021

De-isolation of COVID-19–positive hemodialysis patients in the outpatient setting: a single-center experience

Caroline Dudreuilh 1, Nicola Kumar 1, Vicki Moxham 1, Carolyn Hemsley 2, Simon Goldenberg 2, Dimitrios-Anestis Moutzouris 1,
PMCID: PMC7206422  PMID: 32471644

To the editor:

The advice for patients presenting with coronavirus disease 2019 (COVID-19) symptoms is to self-isolate for 7 days after the onset of symptoms for the individual case and 14 days for the household.1 Dialysis patients can be considered as immunocompromised and display a decreased ability to develop seroconversion to infectious diseases.2 Therefore, 7 to 14 days may not be an appropriate threshold in a dialysis population. In our center, we provide dialysis in 2 hospital-based and 6 satellite units, for a total of 664 patients (see Supplementary Methods). We isolated our COVID-19–positive dialysis outpatients in a dedicated unit and followed a pathway for de-escalation of stable patients with serial COVID-19 swabs, starting 7 days after confirmed diagnosis (Figure 1 , Supplementary Table S1). Thirty-four COVID-19–positive patients who had at least 3 swabs were included: 20 patients were de-isolated in less than 14 days (59%) with 9% on day 9. By day 12, 35% of patients could be dialyzed in their base unit (which is crucial for capacity). However, by day 15, 14 patients (41%) had not cleared the virus and could not be repatriated: 5 patients cleared the virus later (median of 18 days [range, 16–21]) and 9 patients were still positive or had only one negative swab at the end of follow-up. It is unclear whether detection of viral RNA represents the ability to transmit the virus,3 , 4 but until more evidence is available, it would be prudent to isolate patients as discussed to prevent cross-contamination in this high-risk population.

Figure 1.

Figure 1

De-escalation plan for coronavirus disease 2019 (COVID-19)–positive dialysis patients. HD, hemodialysis.

Disclosure

SG reports personal fees from Astellas, Enterobiotix, Menarini, MSD, Pfizer, and Shionogi, outside of the submitted work. All the other authors declared no competing interests.

Footnotes

Supplementary File (PDF)

Supplementary Methods.

Table S1. Demographics of the patients followed-up in a COVID-19–dedicated dialysis unit.

Supplementary Material

Supplementary File (PDF)
mmc1.pdf (235.5KB, pdf)

References

  • 1.Ahmed F., Zviedrite N., Uzicanin A. Effectiveness of workplace social distancing measures in reducing influenza transmission: a systematic review. BMC Public Health. 2018;18:518. doi: 10.1186/s12889-018-5446-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Baragetti I., El Essawy B., Fiorina P. Targeting immunity in end-stage renal disease. Am J Nephrol. 2017;45:310–319. doi: 10.1159/000458768. [DOI] [PubMed] [Google Scholar]
  • 3.To K.K., Tsang O.T., Leung W.S. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20:565–574. doi: 10.1016/S1473-3099(20)30196-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.He X., Lau E.H.Y., Wu P. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26:672–675. doi: 10.1038/s41591-020-0869-5. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary File (PDF)
mmc1.pdf (235.5KB, pdf)

Articles from Kidney International are provided here courtesy of Elsevier

RESOURCES